DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20213650

Prevalence of metabolic syndrome and associated factors among human immunodeficiency virus patients on highly active antiretroviral therapy in North central Nigeria

Rifkatu S. Reng, Gerald A. Onwuegbuzie, Muaz Salisu, Felicia Anumah

Abstract


Background: Metabolic syndrome (MS) is a complex disorder defined by cluster of risk factors for cardiovascular disease and type 2 diabetes mellitus. The Use of Highly active antiretroviral therapy in HIV patients is associated with metabolic syndrome which increases the risk of cardiovascular disease (CVD). The aim of the study was to determine the prevalence of MS among HAART treated HIV patients and HAART naïve patients.

Methods: This was a cross-sectional study that evaluated 581 (396 females, 184 males) consenting HIV patents in the hospital. Clinical characteristics, anthropometry, blood pressure, lipid profile, fasting blood glucose, fasting plasma insulin, CD4 cell counts and viral load were determined using appropriate standard techniques. MS was defined using International Diabetes Federation (IDF) cut-off values.

Results: The overall prevalence of MS was 10.7%, with more females 52 (13.1%) than males 10 (5.4%), p=0.005. MS in patients on HAART was 58 (15.1%) and HAART naive 4 (2.0%). Overall, waist circumference, BMI, systolic blood pressure (BP), diastolic blood pressure (BP), triglycerides and fasting blood glucose were 82.7±11.5, 22.7±, 120.6±17.6, 77.5±10.6, 1.1±0.7 and 5.1±1.9 respectively. Patients with MS had significantly higher (p<0.05) waist circumference (94.1 vs 81.3 cm), BMI (24.8 vs 22.5 kg/m2), systolic BP (135.4 vs 118.8 mmHg), diastolic BP (86.2 vs 76.5 mmHg), triglycerides (1.3 vs 1.0 mmol/l) and fasting blood glucose (6.3 vs 4.9 mmol/l).  Insulin resistance (IR) was higher in patients with MS 11.8(7.9) compared with patients without MS 5.5 (6.8) p=0.02.

Conclusions: Prevalence of metabolic syndrome in this study was lower than that reported in previous works, the prevalence is much higher in the HAART treated patients. The risk of MS were high triglycerides, hypertension and abnormal fasting blood glucose. There was significant association with the traditional risk factors, age, female gender and HIV duration.

 


Keywords


HIV, HAART, Metabolic syndrome, Cardiovascular disease, IDF

Full Text:

PDF

References


Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52.

Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005;366(9491):1059-62.

Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245-50.

Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709-16.

Reng SR, Uloko EA, Puepet HF, Onwuegbuzie AG, Ramalan AMJNJoM. Prevalence and determinants of Glucose Intolerance among HIV/AIDS patients in North-central Nigeria. 2016;25(2):128-33.

Carr A, Samaras K, Chisholm DJ, Cooper DA. Abnormal fat distribution and use of protease inhibitors. Lancet. Jun 6 1998;351(9117):1736.

Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093-9.

Alvarez C, Salazar R, Galindez J, Rangel F, Castaãeda ML, Lopardo G, et al. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis. 2010;14(3):256-63.

Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care. 2002;25(7):1253-4.

Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis. 2007;44(5):726-34.

Jericó C, Knobel H, Montero M, Llanos J, Guelar A, Gimeno JL, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;28(1):132-7.

Muazu SB, Mshelia R, Bako H, Ahmad MB, Mohamad T, Okpe IO, et al. Metabolic syndrome and its associated factors among apparently “healthy” adults residing in rural settlements in Dutse, Northwestern Nigeria: A community-based study. J Health Res Rev. 2019;6(3):95.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. Jul 1985;28(7):412-9.

Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care. 2007;30(1):113-9.

Paula AA, Falcão MC, Pacheco AG. Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. AIDS Res Ther. 2013;10(1):32.

Bernal E, Masiá M, Padilla S, Hidalgo A, Gutiérrez F. Prevalence and characteristics of metabolic syndrome among HIV-infected patients from a Mediterranean cohort. Med Clin (Barc). 2007;128(5):172-5.

Sears S, Buendia JR, Odem S, Qobadi M, Wortley P, Mgbere O, et al. Metabolic Syndrome Among People Living with HIV Receiving Medical Care in Southern United States: Prevalence and Risk Factors. AIDS Behav. 2019;23(11):2916-25.

Ayodele OE, Akinboro AO, Akinyemi SO, Adepeju AA, Akinremi OA, Alao CA, et al. Prevalence and clinical correlates of metabolic syndrome in Nigerians living with human immunodeficiency virus/acquired immunodeficiency syndrome. Metab Syndr Relat Disord. 2012;10(5):373-9.

Todowede OO, Mianda SZ, Sartorius B. Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa-a systematic review and meta-analysis. Syst Rev. 2019;8(1):4.

Theengh DP, Yadav P, Jain AK, Nandy P. Assessment of metabolic syndrome in HIV-infected individuals. Indian J Sex Transm Dis AIDS. 2017;38(2):152-6.

Nguyen KA, Peer N, Mills EJ, Kengne AP. A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population. PloS one. 2016;11(3):150970.

Osoti A, Temu TM, Kirui N, Ngetich EK, Kamano JH, Page S, et al. Metabolic Syndrome Among Antiretroviral Therapy-Naive Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya. AIDS Patient Care STDS. 2018;32(6):215-22.

Bune GT, Yalew AW, Kumie A. The extents of metabolic syndrome among Antiretroviral Therapy exposed and ART naïve adult HIV patients in the Gedeo-zone, Southern-Ethiopia: a comparative cross-sectional study. Arch Public Health. 2020;78:40.

Idiculla J, Ravindra'n GD, D'Souza J, Singh G, Furruqh S. Diabetes mellitus, insulin resistance, and metabolic syndrome in HIV-positive patients in South India. Int J Gen Med. 2011;4:73-8.

Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clinical therapeutics. Jun 2000;22(6):685-708.

Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005;112(5):666-73.